ST. LOUIS, June 06, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces the publication of a special issue of the Journal of Atrial Fibrillation & Electrophysiology (JAFIB – EP) focused on the use of robotic magnetic navigation (NMR) for the treatment of cardiac arrhythmias. The robotics special issue was published in collaboration with the Society for Cardiac Robotic Navigation and includes sixteen peer-reviewed publications that document the clinical value of robotic magnetic navigation, new technologies, and refined workflows across a broad spectrum. cardiac arrhythmias. The journal will also incorporate robotics as a recurring section in future editions.
Physicians from 20 hospitals and universities in North America, Europe and Asia contributed to the sixteen publications of the special issue on robotics. The full issue can be viewed at www.JAFIB-EP.com. Publications cover a wide range of topics, including:
- Historical review and evolution of robotic magnetic navigation
- Reviews of clinical outcomes of large subgroups of patients with atrial fibrillation, ventricular tachycardias, and supraventricular tachycardias
- Robotics enabling fluoro-free cardiac ablation procedures without the use of X-rays
- The use of Stereotaxis robotic technology in conjunction with novel preoperative imaging and a wide range of electrophysiological mapping technologies
- Demonstration of TeleRobotic technology for remote catheter navigation
“Robotics represents an increasingly important technology in the field of electrophysiology,” said Dr. Andrea Natale, editor of the Journal of Atrial Fibrillation & Electrophysiology. “We are thrilled to collaborate with the Society for Cardiac Robotic Navigation on this special issue and help advance clinical science and awareness.”
“We appear to be at an important inflection point in the evolution of robotic magnetic navigation in electrophysiology,” said Dr. J. Peter Weiss, president of the Society for Cardiac Robotic Navigation. “As the field continues to optimize the safety, effectiveness and efficiency of arrhythmia patient care, the growing adoption of robotics and automation is poised to play a critical role. We hope this special edition provides education, motivation, and inspiration to anyone who wants to push the field forward.
The Journal of Atrial Fibrillation & Electrophysiology was founded in 2008. Its mission is to provide a forum for communicating original and innovative research findings relevant to better understanding the pathophysiology of cardiac arrhythmias and improving patient treatment and survival. Tens of millions of people around the world suffer from arrhythmias – abnormal heart rhythms that occur when the heart beats too fast, too slow or irregularly. When left untreated, arrhythmias can significantly increase the risk of stroke, heart failure, and sudden cardiac arrest. Robotic magnetic navigation has the advantages of robotic precision and safety for cardiac ablation. Robotic heart ablation is performed using a soft magnetic catheter navigated inside the heart by a doctor seated in front of a computer cockpit. The doctor navigates the catheter using precise robot-operated magnets positioned on either side of the patient.
“A growing number of scientific publications continue to support the differentiated clinical value of robotics for the treatment of a wide range of arrhythmias,” said David Fischel, president and CEO of Stereotaxis. “We are excited to advance the frontiers of patient care and technology in electrophysiology.”
Stereotaxis is the world leader in innovative robotic technologies designed to improve the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments and information solutions for the interventional laboratory. These innovations help physicians deliver unparalleled patient care with robotic precision and safety, expand access to minimally invasive therapy, and improve productivity, connectivity and intelligence in the operating room. Stereotactic technology has been used to treat over 100,000 patients in the United States, Europe, Asia and elsewhere. For more information, please visit www.stereotaxis.com.
This press release contains statements that may constitute “forward-looking” statements, generally containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, market acceptance of the Company’s products, the effect of global economics on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, reliance on third-party vendors, timing of regulatory approvals, impact of pandemics or other catastrophes and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. In making these forward-looking statements, the Company does not undertake to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments, as some of these purchase orders and other commitments are subject to contingencies beyond the Company’s control and may be revised, modified, delayed or cancelled. .
|Investor contacts:||Media Contact:|
|David L. Fischel||Bethanne Schluter|
|President and CEO||Director, Marketing and Communications|
|Kimberly Peery||[email protected]|